​

Abbott Laboratories (ABT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABT Stock Forecast

Abbott Laboratories stock forecast is as follows: an average price target of $120.09 (represents a 4.44% upside from ABT’s last price of $114.99) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.

ABT Price Target

The average price target for Abbott Laboratories (ABT) is $120.09 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $139.00 to $24.01. This represents a potential 4.44% upside from ABT's last price of $114.99.

ABT Analyst Ratings

Buy

According to 17 Wall Street analysts, Abbott Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for ABT stock is 0 'Strong Buy' (0.00%), 15 'Buy' (88.24%), 2 'Hold' (11.76%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Abbott Laboratories Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 17, 2024Adam MaederPiper Sandler$133.00$117.8212.88%15.66%
Oct 17, 2024Lee HambrightBernstein$138.00$117.8217.13%20.01%
Oct 16, 2024Matthew TaylorJefferies$125.00$117.826.09%8.71%
Oct 16, 2024Vijay KumarEvercore ISI$128.00$117.828.64%11.31%
Oct 16, 2024Marie ThibaultBTIG$139.00$117.8217.98%20.88%
Oct 08, 2024Suraj KaliaOppenheimer$130.00$114.3013.74%13.05%
Oct 08, 2024Charles MinervinoSusquehanna$120.00$114.304.99%4.36%
Oct 08, 2024Shagun SinghRBC Capital$130.00$113.3614.68%13.05%
Sep 19, 2024Scott FortuneRoth Capital$24.01$54.49-55.94%-79.12%
Sep 19, 2024Jonathan AtkinRBC Capital$165.65$54.49204.00%44.06%
Sep 19, 2024Adam MaederPiper Sandler$131.00$114.8814.03%13.92%
Aug 27, 2024Matthew TaylorJefferies$120.00$112.226.93%4.36%
Aug 22, 2024Joanne WuenschCitigroup$127.00$111.3914.01%10.44%
Jul 18, 2024Joanna WienschCitigroup$119.00$104.6813.68%3.49%
Jul 18, 2024Jayson BedfordRaymond James$127.00$104.6821.32%10.44%
Jul 02, 2024Vijay KumarEvercore ISI$120.00$103.2016.28%4.36%
Jun 03, 2024Marie ThibaultBTIG$135.00$102.9931.08%17.40%
May 30, 2024David RomanGoldman Sachs$121.00$100.7320.12%5.23%
Apr 22, 2024Matt MiksicBarclays$140.00$107.0730.76%21.75%
Apr 18, 2024Lee HambrightBernstein$133.00$105.2726.34%15.66%
Apr 18, 2024Shagun SinghRBC Capital$125.00$105.9018.04%8.71%
Jan 06, 2023Morgan Stanley$133.00$111.3719.42%15.66%
Dec 12, 2022Citigroup$125.00$107.5116.27%8.71%
Aug 03, 2022Shagun SinghRBC Capital$132.00$109.7820.24%14.79%
Jul 27, 2022UBS$128.00$109.0917.33%11.31%
Jul 21, 2022Citigroup$123.00$108.2313.65%6.97%
Jul 18, 2022BTIG$126.00$108.3616.28%9.57%
Jul 18, 2022Stifel Nicolaus$126.00$108.4316.20%9.57%
Jul 15, 2022Raymond James$117.00$105.7110.68%1.75%
Jun 27, 2022Marie ThibaultBTIG$130.00$109.4518.78%13.05%
Apr 25, 2022Jayson BedfordRaymond James$135.00$119.6412.84%17.40%
Apr 21, 2022RBC Capital$143.00$122.6416.60%24.36%
Apr 21, 2022Marie ThibaultBTIG$140.00$123.8013.09%21.75%
Apr 20, 2022New Street$117.49$123.41-4.80%2.17%
Apr 11, 2022Larry BiegelsenWells Fargo$150.00$120.0424.96%30.45%
Mar 03, 2022Travis SteedBank of America Securities$140.00$120.9715.73%21.75%
Feb 26, 2022Cecilia FurlongMorgan Stanley$151.00$122.4123.36%31.32%
Feb 06, 2022Jayson BedfordRaymond James$143.00$129.7110.25%24.36%
Dec 15, 2021Joanne WuenschCitigroup$154.00$135.0814.01%33.92%
Oct 21, 2021Raj DenhoyJefferies$145.00$124.6116.36%26.10%
Jul 22, 2021Rick WiseStifel Nicolaus$130.00$117.3810.75%13.05%
Jun 01, 2021Amit HazanGoldman Sachs$120.00$104.6114.71%4.36%
Apr 21, 2021Vijay KumarEvercore ISI$136.00$121.2412.17%18.27%

The latest Abbott Laboratories stock forecast, released on Oct 17, 2024 by Adam Maeder from Piper Sandler, set a price target of $133.00, which represents a 12.88% increase from the stock price at the time of the forecast ($117.82), and a 15.66% increase from ABT last price ($114.99).

Abbott Laboratories Price Target by Period

1M3M12M
# Anlaysts-821
Avg Price Target-$130.38$125.27
Last Closing Price$114.99$114.99$114.99
Upside/Downside-100.00%13.38%8.94%

In the current month, the average price target of Abbott Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Abbott Laboratories's last price of $114.99. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2024William BlairOutperformOutperformHold
Oct 17, 2024Piper SandlerOverweightOverweightHold
Oct 17, 2024UBSBuyBuyHold
Oct 17, 2024BernsteinOutperformOutperformHold
Oct 17, 2024OppenheimerOutperformOutperformHold
Oct 16, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Oct 16, 2024BTIGBuyBuyHold
Oct 16, 2024Piper SandlerBuyOverweightInitialise
Oct 14, 2024Raymond JamesUnderperformUnderperformHold
Oct 14, 2024RBC CapitalBuyBuyHold
Oct 14, 2024Raymond JamesOutperformOutperformHold
Oct 08, 2024Hovde GroupOutperformInitialise
Oct 08, 2024SusquehannaPositiveInitialise
Oct 08, 2024RBC CapitalOutperformOutperformHold
Oct 08, 2024OppenheimerOutperformInitialise
Oct 03, 2024Cowen & Co.BuyBuyHold
Oct 01, 2024Evercore ISIOutperformOutperformHold
Sep 26, 2024Piper SandlerBuyBuyHold
Sep 26, 2024JefferiesUnderperformUnderperformHold
Sep 26, 2024JefferiesHoldHoldHold
Sep 19, 2024RBC CapitalBuySector PerformInitialise
Sep 19, 2024Piper SandlerOverweightInitialise
Sep 05, 2024Cowen & Co.BuyBuyHold
Aug 27, 2024JefferiesHoldHoldHold
Aug 22, 2024RBC CapitalBuyBuyHold
Aug 22, 2024Goldman SachsUnderperformUnderperformHold
Aug 21, 2024CitigroupBuyBuyHold
Jul 29, 2024Edward JonesHoldDowngrade
Jul 18, 2024Raymond JamesOutperformOutperformHold
Jul 18, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 18, 2024CitigroupBuyBuyHold
Jul 18, 2024BarclaysOverweightOverweightHold
Jul 02, 2024RBC CapitalBuyBuyHold
Jul 02, 2024Evercore ISIOutperformOutperformHold
Jun 24, 2024Cowen & Co.BuyBuyHold
Jun 06, 2024Zacks Investment ResearchPerformPerformHold
Jun 03, 2024BTIGBuyBuyHold
May 30, 2024Goldman SachsBuyInitialise
Apr 22, 2024BarclaysOverweightOverweightHold
Apr 18, 2024BernsteinOutperformOutperformHold
Apr 18, 2024RBC CapitalOutperformOutperformHold
Apr 03, 2024Raymond JamesUnderperformUnderperformHold
Apr 03, 2024RBC CapitalBuyBuyHold
Apr 03, 2024CitigroupBuyBuyHold
Oct 19, 2023Wells FargoOverweightOverweightHold
Oct 19, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Oct 19, 2023Raymond JamesOutperformOutperformHold
Jul 24, 2023BarclaysOverweightOverweightHold
Jul 21, 2023CitigroupBuyBuyHold
Apr 20, 2023UBSBuyBuyHold
Apr 19, 2023CitigroupBuyBuyHold
Jan 06, 2023Morgan StanleyOverweightOverweightHold
Dec 12, 2022CitigroupBuyBuyHold
Jul 27, 2022UBSBuyBuyHold
Jul 21, 2022RBC CapitalOutperformOutperformHold
Jul 21, 2022CitigroupBuyBuyHold
Jul 18, 2022BTIGBuyBuyHold
Jul 15, 2022Raymond JamesOutperformOutperformHold
Jul 14, 2022Cowen & Co.OutperformOutperformHold
Jun 24, 2022BTIGBuyBuyHold
May 17, 2022CitigroupBuyBuyHold
Apr 24, 2022Raymond JamesOutperformOutperformHold
Apr 11, 2022Wells FargoOverweightOverweightHold
Feb 26, 2022Morgan StanleyTop PickTop PickHold
Feb 06, 2022Raymond JamesOutperformOutperformHold
Jul 25, 2021Raymond JamesOutperformOutperformHold
Sep 18, 2020Wolfe ResearchOutperformInitialise

Abbott Laboratories's last stock rating was published by William Blair on Oct 17, 2024. The company gave ABT a "Outperform" rating, the same as its previous rate.

Abbott Laboratories Financial Forecast

Abbott Laboratories Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$10.24B$10.14B$9.98B$9.75B$10.09B$10.41B$11.26B$11.89B$11.47B$10.93B$10.22B$10.46B$10.70B$8.85B$7.33B$7.73B$8.31B$8.08B
Avg Forecast$12.75B$12.30B$11.98B$11.44B$11.84B$11.41B$11.16B$10.65B$11.03B$10.55B$10.37B$9.88B$10.19B$9.84B$9.71B$9.67B$9.66B$9.65B$10.33B$11.00B$10.71B$9.56B$9.69B$10.69B$9.94B$8.54B$6.81B$7.44B$8.27B$8.11B
High Forecast$12.92B$12.46B$12.14B$11.59B$11.99B$11.56B$11.31B$10.80B$11.11B$10.56B$10.37B$9.88B$10.37B$9.97B$9.84B$9.79B$9.79B$9.74B$10.42B$11.10B$10.81B$9.65B$9.78B$10.79B$10.03B$8.62B$6.87B$7.51B$8.34B$8.18B
Low Forecast$12.54B$12.11B$11.79B$11.26B$11.65B$11.23B$10.98B$10.48B$10.91B$10.54B$10.37B$9.88B$10.07B$9.68B$9.56B$9.51B$9.51B$9.53B$10.20B$10.86B$10.58B$9.45B$9.57B$10.56B$9.82B$8.44B$6.73B$7.35B$8.17B$8.01B
# Analysts10755854111495101155954475510791599168
Surprise %------------1.01%1.03%1.03%1.01%1.04%1.08%1.09%1.08%1.07%1.14%1.06%0.98%1.08%1.04%1.08%1.04%1.01%1.00%

Abbott Laboratories's average Quarter revenue forecast for Mar 24 based on 10 analysts is $9.88B, with a low forecast of $9.88B, and a high forecast of $9.88B. ABT's average Quarter revenue forecast represents a -3.49% decrease compared to the company's last Quarter revenue of $10.24B (Dec 23).

Abbott Laboratories EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111495101155954475510791599168
EBITDA------------$2.66B$2.23B$2.22B$2.11B$1.87B$2.36B$2.96B$3.50B$3.34B$3.47B$2.36B$3.11B$3.39B$2.37B$1.49B$1.62B$2.16B$2.02B
Avg Forecast$3.42B$3.30B$3.22B$3.07B$3.18B$3.06B$2.99B$2.86B$2.96B$2.83B$2.78B$3.81B$2.73B$2.64B$2.61B$3.47B$3.34B$2.29B$2.45B$3.15B$2.54B$2.27B$2.30B$2.99B$2.36B$2.03B$1.62B$1.42B$1.96B$1.92B
High Forecast$3.47B$3.34B$3.26B$3.11B$3.22B$3.10B$3.03B$2.90B$2.98B$2.83B$2.78B$4.58B$2.78B$2.67B$2.64B$4.16B$4.01B$2.31B$2.47B$3.78B$2.56B$2.29B$2.32B$3.59B$2.38B$2.05B$1.63B$1.71B$1.98B$1.94B
Low Forecast$3.37B$3.25B$3.16B$3.02B$3.12B$3.01B$2.95B$2.81B$2.93B$2.83B$2.78B$3.05B$2.70B$2.60B$2.56B$2.77B$2.67B$2.26B$2.42B$2.52B$2.51B$2.24B$2.27B$2.39B$2.33B$2.00B$1.60B$1.14B$1.94B$1.90B
Surprise %------------0.97%0.84%0.85%0.61%0.56%1.03%1.21%1.11%1.31%1.53%1.02%1.04%1.44%1.17%0.92%1.14%1.10%1.05%

10 analysts predict ABT's average Quarter EBITDA for Mar 24 to be $3.81B, with a high of $4.58B and a low of $3.05B. This is 43.19% upper than Abbott Laboratories's previous annual EBITDA (Dec 23) of $2.66B.

Abbott Laboratories Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111495101155954475510791599168
Net Income------------$1.59B$1.44B$1.38B$1.32B$1.03B$1.44B$2.02B$2.45B$1.99B$2.10B$1.19B$1.79B$2.16B$1.23B$537.00M$564.00M$1.05B$960.00M
Avg Forecast$2.80B$2.59B$2.48B$2.20B$2.54B$2.33B$2.21B$1.95B$2.35B$2.10B$1.93B$2.44B$2.08B$1.92B$1.83B$2.22B$1.99B$1.65B$1.97B$2.01B$2.11B$1.65B$1.78B$1.72B$2.36B$1.59B$730.26M$495.93M$1.65B$1.47B
High Forecast$2.85B$2.63B$2.52B$2.24B$2.59B$2.37B$2.25B$2.08B$2.39B$2.10B$1.93B$2.92B$2.11B$1.96B$1.87B$2.66B$2.39B$1.67B$1.99B$2.42B$2.13B$1.67B$1.79B$2.07B$2.39B$1.61B$739.07M$595.12M$1.67B$1.49B
Low Forecast$2.74B$2.53B$2.43B$2.15B$2.49B$2.28B$2.16B$1.88B$2.33B$2.10B$1.93B$1.95B$2.06B$1.88B$1.80B$1.77B$1.59B$1.62B$1.95B$1.61B$2.08B$1.63B$1.77B$1.38B$2.33B$1.56B$718.81M$396.74M$1.63B$1.45B
Surprise %------------0.77%0.75%0.75%0.59%0.52%0.87%1.02%1.21%0.94%1.27%0.67%1.04%0.91%0.78%0.74%1.14%0.63%0.65%

Abbott Laboratories's average Quarter net income forecast for Mar 24 is $2.44B, with a range of $1.95B to $2.92B. ABT's average Quarter net income forecast represents a 52.90% increase compared to the company's last Quarter net income of $1.59B (Dec 23).

Abbott Laboratories SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111495101155954475510791599168
SG&A------------$2.70B$2.72B$2.74B$2.76B$2.97B$2.73B$2.76B$2.79B$3.05B$2.77B$2.73B$2.78B$2.57B$2.30B$2.28B$2.55B$2.41B$2.44B
Avg Forecast$3.52B$3.39B$3.31B$3.16B$3.27B$3.15B$3.08B$2.94B$3.04B$2.91B$2.86B$2.78B$2.81B$2.72B$2.68B$2.52B$3.05B$2.66B$2.85B$2.29B$2.95B$2.64B$2.67B$2.67B$2.74B$2.36B$1.88B$2.24B$2.28B$2.24B
High Forecast$3.56B$3.44B$3.35B$3.20B$3.31B$3.19B$3.12B$2.98B$3.07B$2.91B$2.86B$3.33B$2.86B$2.75B$2.72B$3.03B$3.66B$2.69B$2.88B$2.75B$2.98B$2.66B$2.70B$3.21B$2.77B$2.38B$1.90B$2.69B$2.30B$2.26B
Low Forecast$3.46B$3.34B$3.25B$3.11B$3.21B$3.10B$3.03B$2.89B$3.01B$2.91B$2.86B$2.22B$2.78B$2.67B$2.64B$2.02B$2.44B$2.63B$2.81B$1.84B$2.92B$2.61B$2.64B$2.14B$2.71B$2.33B$1.86B$1.79B$2.25B$2.21B
Surprise %------------0.96%1.00%1.02%1.09%0.98%1.03%0.97%1.21%1.03%1.05%1.02%1.04%0.94%0.98%1.21%1.14%1.06%1.09%

Abbott Laboratories's average Quarter SG&A projection for Mar 24 is $2.78B, based on 10 Wall Street analysts, with a range of $2.22B to $3.33B. The forecast indicates a 2.66% rise compared to ABT last annual SG&A of $2.70B (Dec 23).

Abbott Laboratories EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111495101155954475510791599168
EPS------------$0.91$0.83$0.79$0.76$0.59$1.15$1.15$1.40$1.13$1.19$0.67$1.01$1.22$0.70$0.30$0.32$0.60$0.54
Avg Forecast$1.60$1.48$1.42$1.26$1.45$1.33$1.26$1.11$1.34$1.20$1.10$0.95$1.19$1.10$1.05$0.99$0.93$0.94$1.13$1.47$1.21$0.94$1.02$1.27$1.35$0.91$0.42$0.59$0.95$0.84
High Forecast$1.63$1.50$1.44$1.28$1.48$1.35$1.29$1.19$1.36$1.20$1.10$0.95$1.21$1.12$1.07$1.01$0.94$0.95$1.14$1.48$1.22$0.96$1.02$1.29$1.37$0.92$0.42$0.60$0.96$0.85
Low Forecast$1.57$1.45$1.39$1.23$1.42$1.30$1.24$1.07$1.33$1.20$1.10$0.95$1.18$1.08$1.03$0.97$0.91$0.93$1.11$1.45$1.19$0.93$1.01$1.25$1.33$0.89$0.41$0.58$0.93$0.83
Surprise %------------0.76%0.75%0.75%0.77%0.64%1.22%1.02%0.96%0.94%1.26%0.66%0.79%0.90%0.77%0.73%0.54%0.63%0.65%

According to 10 Wall Street analysts, Abbott Laboratories's projected average Quarter EPS for Mar 24 is $0.95, with a low estimate of $0.95 and a high estimate of $0.95. This represents a 4.95% increase compared to ABT previous annual EPS of $0.91 (Dec 23).

Abbott Laboratories Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
LLYEli Lilly and$783.17$1.03K31.19%Buy
JNJJohnson & Johnson$145.05$175.1320.74%Buy
ABBVAbbVie$178.01$211.2018.65%Buy
MDTMedtronic$80.74$95.4018.16%Hold
ABTAbbott Laboratories$114.99$120.094.44%Buy
BMYBristol-Myers Squibb$57.68$50.50-12.45%Hold

ABT Forecast FAQ

Is Abbott Laboratories a good buy?

Yes, according to 17 Wall Street analysts, Abbott Laboratories (ABT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 88.24% of ABT's total ratings.

What is ABT's price target?

Abbott Laboratories (ABT) average price target is $120.09 with a range of $24.01 to $139, implying a 4.44% from its last price of $114.99. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Abbott Laboratories stock go up soon?

According to Wall Street analysts' prediction for ABT stock, the company can go up by 4.44% (from the last price of $114.99 to the average price target of $120.09), up by 20.88% based on the highest stock price target, and down by -79.12% based on the lowest stock price target.

Can Abbott Laboratories stock reach $200?

ABT's average twelve months analyst stock price target of $120.09 does not support the claim that Abbott Laboratories can reach $200 in the near future.

What are Abbott Laboratories's analysts' financial forecasts?

Abbott Laboratories's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.06B (high $45.66B, low $44.34B), average EBITDA is $12.09B (high $12.25B, low $11.89B), average net income is $9.02B (high $9.29B, low $8.81B), average SG&A $12.43B (high $12.6B, low $12.24B), and average EPS is $5.16 (high $5.31, low $5.04). ABT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $48.47B (high $49.11B, low $47.7B), average EBITDA is $13B (high $13.18B, low $12.8B), average net income is $10.06B (high $10.24B, low $9.86B), average SG&A $13.38B (high $13.55B, low $13.16B), and average EPS is $5.76 (high $5.86, low $5.64).

Did the ABT's actual financial results beat the analysts' financial forecasts?

Based on Abbott Laboratories's last annual report (Dec 2023), the company's revenue was $40.11B, beating the average analysts forecast of $39.4B by 1.79%. Apple's EBITDA was $9.93B, missing the average prediction of $11.45B by -13.21%. The company's net income was $5.72B, missing the average estimation of $8.05B by -28.94%. Apple's SG&A was $10.86B, beating the average forecast of $10.73B by 1.20%. Lastly, the company's EPS was $3.26, missing the average prediction of $4.33 by -24.72%. In terms of the last quarterly report (Dec 2023), Abbott Laboratories's revenue was $10.24B, beating the average analysts' forecast of $10.19B by 0.54%. The company's EBITDA was $2.66B, missing the average prediction of $2.73B by -2.51%. Abbott Laboratories's net income was $1.59B, missing the average estimation of $2.08B by -23.34%. The company's SG&A was $2.7B, missing the average forecast of $2.81B by -3.80%. Lastly, the company's EPS was $0.91, missing the average prediction of $1.19 by -23.50%